mer
cluster
three
case
mer
uk
identifi
septemb
ref
merscov
continu
emerg
spread
countri
outsid
arabian
peninsula
result
travel
infect
person
often
import
mer
case
result
nosocomi
transmiss
may
singl
person
return
middl
east
start
nosocomi
outbreak
mer
south
korea
involv
hospit
patient
april
confirm
case
mer
includ
death
countri
review
highlight
pandem
epidem
potenti
emerg
coronavirus
discuss
current
knowledg
biolog
sarscov
merscov
includ
transmiss
pathogenesi
develop
medic
countermeasur
key
featur
virus
domin
nosocomi
transmiss
pathogenesi
driven
combin
viral
replic
lower
respiratori
tract
aberr
host
immun
respons
sever
potenti
treatment
sar
mer
identifi
anim
vitro
model
includ
smallmolecul
proteas
inhibitor
neutral
antibodi
inhibitor
host
immun
respons
howev
efficaci
data
human
clinic
trial
lack
need
move
potenti
countermeasur
forward
respect
fig
similarli
virus
order
nidoviral
sarscov
merscov
uniqu
code
strategi
twothird
viral
rna
translat
two
larg
polyprotein
remaind
viral
genom
transcrib
nest
set
subgenom
mrna
fig
two
polyprotein
encod
nonstructur
protein
make
viral
replicasetranscriptas
complex
polyprotein
cleav
two
proteas
papainlik
proteas
plpro
correspond
main
proteas
proteas
correspond
nsp
rearrang
membran
deriv
rough
endoplasm
reticulum
rer
doublemembran
vesicl
viral
replic
transcript
occur
one
uniqu
featur
coronavirus
exoribonucleas
exon
function
ref
provid
proofread
capabl
requir
maintain
larg
rna
genom
without
accumul
detriment
mutat
sarscov
merscov
transcrib
subgenom
rna
ergolgi
intermedi
compart
ergic
cellular
compart
facilit
transport
endoplasm
reticulum
er
golgi
complex
infect
individu
infect
disproportion
larg
number
secondari
case
respect
encod
four
structur
protein
spike
envelop
e
membran
nucleocapsid
n
well
sever
accessori
protein
involv
viral
replic
interfer
host
innat
immun
respons
unknown
poorli
understood
function
envelop
spike
glycoprotein
bind
cellular
receptor
angiotensinconvert
enzym
sarscov
dipeptidyl
peptidas
merscov
membran
fusion
either
directli
host
cell
membran
endosom
membran
viral
rna
genom
releas
cytoplasm
rna
uncoat
allow
translat
two
polyprotein
transcript
subgenom
rna
replic
viral
genom
fig
newli
form
envelop
glycoprotein
insert
rer
golgi
membran
genom
rna
nucleocapsid
protein
combin
form
nucleocapsid
viral
particl
bud
ergolgi
intermedi
compart
ergic
virioncontain
vesicl
subsequ
fuse
plasma
membran
releas
viru
first
indic
sourc
sarscov
detect
viru
mask
palm
civet
raccoon
dog
detect
antibodi
viru
chines
ferret
badger
liveanim
market
shenzhen
china
howev
anim
incident
host
evid
circul
sarscovlik
virus
palm
civet
wild
breed
facil
rather
bat
reservoir
wide
varieti
coronavirus
includ
sarscovlik
merscovlik
virus
fig
thu
search
reservoir
merscov
initi
focus
bat
serolog
survey
dromedari
camel
oman
canari
island
show
high
preval
merscovneutr
antibodi
anim
addit
merscov
rna
detect
swab
collect
dromedari
camel
farm
qatar
link
two
human
case
mer
infecti
viru
isol
dromedari
camel
saudi
arabia
qatar
serolog
evid
circul
merscovlik
viru
dromedari
camel
obtain
middl
east
eastern
africa
northern
africa
date
back
far
ref
dromedari
camel
saudi
arabia
harbour
sever
viral
genet
lineag
includ
caus
human
outbreak
taken
togeth
data
strongli
point
role
dromedari
camel
reservoir
merscov
ubiqu
infect
dromedari
camel
close
human
result
continu
zoonot
transmiss
may
explain
merscov
continu
caus
infect
human
wherea
sarscov
without
continu
presenc
infect
intermedi
host
rel
infrequ
humanbat
interact
caus
infect
human
humantohuman
transmiss
sarscov
merscov
occur
mainli
nosocomi
transmiss
mer
case
individu
outbreak
link
hospit
similar
observ
made
sar
cluster
transmiss
famili
member
occur
mer
case
sar
case
transmiss
merscov
patient
common
rout
infect
case
wherea
sarscov
infect
health
care
worker
infect
patient
frequent
predomin
nosocomi
transmiss
probabl
due
fact
substanti
viru
shed
occur
onset
symptom
patient
alreadi
seek
medic
care
analysi
hospit
surfac
treatment
patient
mer
show
ubiquit
presenc
viral
rna
environ
sever
day
patient
longer
test
posit
moreov
mani
patient
sar
mer
infect
super
spreader
clinic
cours
sar
mer
remark
similar
although
subtl
differ
box
owe
current
sparsiti
data
human
merscov
infect
pathogenesi
viru
poorli
understood
howev
similar
mechan
may
underli
pathogenesi
mer
sar
bind
spike
protein
subsequ
downregul
receptor
contribut
lung
injuri
sar
although
seem
counterintuit
receptor
downregul
would
increas
patholog
shown
protect
acut
lung
injuri
downregul
result
excess
product
angiotensin
ii
relat
enzym
ace
suggest
stimul
type
angiotensin
ii
receptor
middl
east
respiratori
syndrom
coronaviru
merscov
encod
two
larg
polyprotein
proteolyt
cleav
nonstructur
protein
nsp
includ
papainlik
proteas
plpro
proteas
rnadepend
rna
polymeras
rdrp
helicas
hel
exonucleas
exon
addit
orf
encod
transcript
nest
set
subgenom
rna
sarscov
merscov
form
spheric
particl
consist
four
structur
protein
envelop
glycoprotein
spike
form
layer
glycoprotein
protrud
envelop
two
addit
transmembran
glycoprotein
incorpor
virion
envelop
e
membran
insid
viral
envelop
resid
helic
nucleocapsid
consist
viral
positivesens
rna
rna
genom
encapsid
protein
nucleocapsid
n
b
follow
entri
viru
host
cell
viral
rna
uncoat
cytoplasm
translat
produc
cleav
proteas
encod
yield
nsp
form
rna
replicasetranscriptas
complex
complex
local
modifi
intracellular
membran
deriv
rough
endoplasm
reticulum
er
perinuclear
region
drive
product
negativesens
rna
rna
replic
transcript
replic
fulllength
rna
copi
genom
produc
use
templat
fulllength
rna
genom
transcript
subset
subgenom
rna
includ
encod
structur
protein
produc
discontinu
transcript
process
subgenom
rna
synthes
combin
vari
length
genom
leader
sequenc
necessari
translat
subgenom
rna
transcrib
subgenom
mrna
although
differ
subgenom
mrna
may
contain
sever
orf
first
orf
closest
translat
result
structur
protein
assembl
nucleocapsid
viral
envelop
ergolgi
intermedi
compart
ergic
follow
releas
nascent
virion
infect
cell
one
panel
recombin
inbr
mous
strain
deriv
genet
divers
set
founder
strain
design
analysi
complex
trait
aggreg
leukocyt
around
blood
vessel
increas
pulmonari
vascular
permeabl
thu
potenti
explain
increas
lung
patholog
express
decreas
immunopatholog
immun
respons
essenti
resolut
infect
also
result
immunopathogenesi
one
indic
immunopathogenesi
may
contribut
sar
observ
viral
load
found
decreas
diseas
sever
increas
unclear
whether
similar
trend
appli
mer
moreov
progress
acut
respiratori
distress
syndrom
ard
associ
upregul
proinflammatori
cytokin
chemokin
particularli
cxcchemokin
ligand
ccchemokin
ligand
increas
plasma
level
molecul
detect
patient
sar
retrospect
longitudin
studi
patient
recov
sar
versu
succumb
diseas
shown
earli
express
protein
encod
ifnstimul
gene
isg
patient
patient
surviv
gene
express
profil
indic
develop
adapt
immun
respons
contrast
patient
succumb
maintain
high
level
isgencod
protein
wherea
spikespecif
antibodi
present
low
level
absent
suggest
sever
diseas
relat
lack
switch
innat
immun
respons
adapt
immun
respons
experi
use
collabor
cross
mous
line
mouseadapt
sarscov
identifi
one
host
gene
import
sar
pathogenesi
although
differ
clinic
sign
viral
replic
mice
compar
wildtyp
mice
perivascular
cuf
number
inflammatori
cell
lung
reduc
mice
biolog
process
small
rna
molecul
induc
degrad
specif
mrna
molecul
therebi
inhibit
gene
express
system
dna
molecul
produc
contain
viral
leader
trailer
sequenc
assay
report
replac
viral
orf
combin
express
viral
protein
tran
system
use
model
viral
life
cycl
without
necess
use
infecti
viru
involv
host
immun
respons
pathogenesi
sar
like
also
mer
suggest
drug
inhibit
viral
replic
need
combin
treatment
control
detriment
immun
respons
immun
evas
sarscov
merscov
use
sever
strategi
avoid
innat
immun
respons
viral
pathogenassoci
molecular
pattern
pamp
doublestrand
rna
dsrna
uncap
mrna
detect
pattern
recognit
receptor
prr
retino
acidinduc
gene
protein
rigi
also
known
melanoma
differentiationassoci
protein
also
known
trigger
complex
signal
cascad
involv
lead
product
type
ifn
activ
transcript
factor
nuclear
turn
activ
induc
transcript
proinflammatori
cytokin
fig
type
ifn
signal
receptor
ifnar
downstream
molecul
signal
transduc
activ
transcript
stat
protein
stimul
product
antivir
protein
encod
isg
ifninduc
protein
tetratricopeptid
repeat
fig
collect
establish
antivir
immun
respons
limit
viral
replic
infect
neighbour
cell
fig
infect
knockout
mice
reveal
import
innat
immun
infect
mice
mice
defici
ifn
receptor
mouseadapt
strain
sarscov
result
sever
diseas
infect
nonadapt
sarscov
strain
moreov
merscov
infect
wildtyp
mice
transduc
human
caus
mild
diseas
symptom
sever
mice
mice
sarscov
merscov
avoid
host
detect
dsrna
replic
virusinduc
doublemembran
vesicl
lack
prr
moreov
recognit
sarscov
mrna
exampl
prevent
cap
viral
mrna
complex
recombin
sarscov
lack
methyl
activ
attenu
exhibit
increas
sensit
type
ifn
effect
depend
viru
attenu
mice
defici
either
molecul
although
mrna
cap
yet
shown
merscov
structur
similar
merscov
complex
sarscov
complex
suggest
similar
mechan
exist
avoid
host
recognit
merscov
mrna
cytosol
prr
sarscov
encod
least
eight
protein
interact
signal
cascad
downstream
prr
merscov
sever
protein
identifi
similar
function
fig
nucleocapsid
protein
sarscov
associ
suppress
rnai
mammalian
cell
furthermor
protein
antagon
ifn
induct
probabl
earli
signal
cascad
downstream
signal
molecul
reliev
inhibit
merscov
similar
ifnantagonist
function
involv
bind
dsrna
subsequ
inhibit
activ
potenti
interact
ifninduc
dsrnadepend
protein
kinas
activ
prkra
also
known
pact
interact
rigi
moreov
merscov
membran
protein
inhibit
nuclear
traffick
ifnregulatori
factor
activ
ifnb
promot
viral
protein
except
also
inhibit
express
gene
control
ifnstimul
respons
element
isr
reduc
express
gene
stimul
final
merscov
interact
inhibitor
therebi
suppress
interact
mitochondri
antiviralsignal
protein
mav
inhibit
phosphoryl
ref
membran
protein
sarscov
inhibit
format
signal
complex
contain
thu
repress
activ
induct
type
ifn
express
membran
protein
merscov
inhibit
function
express
gene
regul
isr
includ
whether
occur
mechan
similar
sarscov
unclear
sarscov
plpro
disrupt
signal
block
phosphoryl
indirectli
furthermor
sarscov
plpro
inhibit
induct
type
ifn
potenti
deubiquityl
phosphoryl
ref
similar
function
describ
merscov
plpro
experi
involv
recombinantli
express
protein
vitro
translat
protein
overexpress
minireplicon
system
shown
sarscov
block
ifn
respons
inhibit
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
incub
period
day
patient
develop
diseas
within
day
exposur
common
earli
symptom
fever
chill
cough
malais
myalgia
headach
less
common
symptom
includ
diarrhoea
vomit
nausea
upper
respiratori
tract
symptom
viral
shed
rare
explain
difficulti
obtain
laboratori
diagnosi
nasal
nasopharyng
swab
abnorm
chest
xray
common
patient
mer
sar
accordingli
patient
sar
requir
intens
care
subsequ
mechan
ventil
wherea
patient
mer
requir
intens
care
higher
incid
acut
respiratori
distress
syndrom
ard
individu
mer
reflect
case
fatal
rate
mer
compar
sar
comorbid
import
role
sar
mer
sever
risk
factor
associ
poor
diseas
outcom
especi
advanc
age
male
sex
mer
addit
risk
factor
poor
outcom
includ
diabet
mellitu
hypertens
cancer
renal
lung
diseas
coinfect
health
care
set
seem
increas
risk
viral
transmiss
owe
aerosolgener
procedur
intub
bronchoscopi
appropri
hospit
hygien
practic
awar
crucial
limit
futur
nosocomi
outbreak
sarscov
also
suggest
ifn
antagonist
underli
mechan
unknown
inhibitor
mavsinduc
apoptosi
howev
occur
ifnindepend
mechan
final
transcriptom
proteom
analysi
human
airway
cell
cultur
show
merscov
sarscov
induc
repress
histon
modif
downregul
express
certain
isg
note
interact
sarscov
merscov
protein
innat
immun
pathway
establish
vitro
system
reli
overexpress
viral
follow
prrmediat
detect
pamp
result
interact
prr
mitochondri
antiviralsignal
protein
mav
activ
nuclear
signal
cascad
involv
sever
kinas
activ
transloc
nucleu
induc
transcript
proinflammatori
cytokin
kinas
also
phosphoryl
p
ifnregulatori
factor
form
homodim
heterodim
enter
nucleu
initi
transcript
type
interferon
type
ifn
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
develop
mechan
interfer
signal
pathway
shown
subvers
strategi
involv
structur
protein
membran
nucleocapsid
n
nonstructur
protein
papainlik
proteas
plpro
indic
figur
nsp
number
letter
b
bind
type
ifn
dimer
receptor
receptor
ifnar
activ
janu
kinas
jak
signal
transduc
activ
transcript
stat
signal
pathway
kinas
phosphoryl
form
complex
complex
move
nucleu
initi
transcript
ifnstimul
gene
isg
control
promot
contain
ifnstimul
respons
element
isr
collect
express
cytokin
ifn
isg
establish
antivir
innat
immun
respons
limit
viral
replic
infect
neighbour
cell
viral
protein
shown
inhibit
host
signal
pathway
evad
immun
respons
broadli
activ
antivir
nucleosid
analogu
sever
direct
indirect
mechan
action
mainli
use
treatment
hepat
c
combin
interferon
polyethylen
glycol
peg
attach
drug
exampl
moieti
improv
solubl
decreas
immunogen
increas
stabil
drug
interest
therebi
allow
reduc
dose
frequenc
use
tabl
sarscov
includ
use
antibodi
ifn
inhibitor
viral
host
proteas
hostdirect
therapi
absenc
clinic
proven
effect
antivir
therapi
sarscov
merscov
patient
mainli
receiv
support
care
often
supplement
differ
combin
drug
ribavirin
variou
type
ifn
given
patient
mer
saudi
arabia
china
typic
combin
broadspectrum
antibiot
oxygen
efficaci
treatment
sarscov
merscov
infect
current
remain
unclear
addit
treatment
mer
typic
start
late
diseas
stage
immunopatholog
predomin
antivir
drug
like
provid
littl
benefit
ribavirin
use
frequent
sar
outbreak
often
combin
corticosteroid
antiinflammatori
effect
also
given
usual
combin
immunoglobulin
thymosin
stimul
develop
cell
small
number
case
combin
ribavirin
none
treatment
test
clinic
trial
make
difficult
assess
efficaci
fact
retrospect
analysi
yield
treatment
combin
clearli
effect
moreov
data
patient
contradictori
whether
ribavirin
use
alon
provid
benefit
possibl
even
detriment
vitro
coronavirus
lower
sensit
ribavirin
virus
delet
sequenc
increas
sensit
coronavirus
ribavirin
howev
underli
mechan
unclear
relat
proofread
function
ref
therefor
ribavirin
consid
combin
antivir
treatment
although
ifn
effect
merscov
vitro
effect
human
yet
prove
effect
ifn
increas
vitro
ribavirin
ad
combin
use
two
drug
reduc
diseas
sever
rhesu
macaqu
model
mer
potenti
side
effect
treatment
fatigu
depress
anaemia
inhibit
use
firstlin
treatment
mer
gener
administ
patient
condit
start
deterior
exampl
one
studi
five
patient
infect
merscov
indic
surviv
follow
ribavirin
therapi
howev
therapi
start
day
admiss
separ
studi
found
improv
surviv
day
mer
diagnosi
start
treatment
day
third
studi
combin
ribavirin
ribavirin
improv
surviv
howev
patient
year
old
preexist
renal
failur
singl
case
ribavirin
start
shortli
admiss
hospit
patient
start
improv
day
admiss
made
complet
recoveri
potent
inhibitor
merscov
replic
vitro
type
ifn
improv
outcom
diseas
observ
common
marmoset
challeng
merscov
thu
type
ifn
use
treatment
human
reconsid
usual
use
furthermor
ribavirin
andor
ifn
test
clinic
trial
determin
efficaci
mer
treatment
establish
treatment
protocol
addit
antivir
treatment
proteas
inhibitor
lopinavir
ritonavir
use
combin
treat
infect
hiv
improv
outcom
patient
sar
combin
ribavirin
compar
patient
treat
ribavirin
alon
lopinavir
show
clear
antivir
activ
merscov
vitro
thu
rare
use
patient
mer
howev
lopinavir
ritonavir
improv
outcom
common
marmoset
treatment
initi
hour
infect
merscov
thu
test
lopinavir
ritonavir
clinic
trial
patient
mer
reconsid
one
patient
receiv
pegyl
ribavirin
lopinavir
ritonavir
combin
undetect
level
merscov
blood
day
initi
therapi
howev
patient
surviv
combin
ribavirin
lopinavir
ritonavir
also
use
mer
treatment
south
korea
efficaci
data
yet
avail
howev
three
case
report
indic
recoveri
five
seven
patient
treat
combin
plpro
essenti
cleavag
viral
polyprotein
distinct
cellular
proteas
ideal
drug
target
particular
plpro
compound
mimic
biolog
activ
peptid
protein
complementactiv
molecul
import
recruit
activ
inflammatori
cell
lung
involv
viral
replic
ifn
antagon
inde
antivir
druglik
molecul
develop
plpro
aid
rapid
report
crystal
structur
proteas
plpro
initi
identifi
drugabl
target
sarscov
recent
note
compound
target
plpro
sarscov
also
activ
plpro
merscov
exampl
inhibit
merscov
sarscov
vitro
howev
efficaci
molecul
yet
test
vivo
mycophenol
acid
also
inhibit
replic
merscov
vitro
inhibit
plpro
effect
marmoset
new
coronavirus
like
emerg
bat
proteas
inhibitor
design
bat
coronavirus
goal
develop
univers
antivir
compound
emerg
zoonot
coronavirus
approach
yield
inhibitor
tylonycteri
bat
coronaviru
close
relat
merscov
inhibitor
name
inde
inhibit
merscov
replic
vitro
similarli
peptidomimet
target
inhibit
merscov
pipistrellu
bat
coronaviru
also
identifi
yet
progress
beyond
vitro
stage
sever
drug
approv
use
human
shown
inhibit
replic
merscov
vitro
notabl
chloroquin
chlorpromazin
loperamid
cyclosporin
although
mechan
action
unknown
benefit
cyclosporin
patient
debat
owe
immunosuppress
effect
drug
although
cyclophilin
inhibitor
result
immunosuppress
avail
activ
merscov
yet
test
antibodi
plasma
therapi
plasma
convalesc
patient
andor
antibodi
therapi
lead
propos
treatment
mer
far
sever
potenti
advantag
approach
exampl
case
number
increas
pool
survivor
becom
larger
provid
individu
suffici
high
antibodi
titr
will
abl
donat
plasma
lowtech
reason
safe
treatment
option
furthermor
gener
monoclon
antibodi
use
human
well
establish
fairli
straightforward
path
safeti
efficaci
test
howev
date
report
use
convalesc
plasma
none
use
monoclon
antibodi
treatment
acut
sever
respiratori
diseas
human
post
hoc
metaanalysi
studi
either
sar
sever
influenza
found
signific
reduct
pool
odd
mortal
convalesc
plasma
use
howev
studi
design
rate
low
low
qualiti
gener
lack
control
group
moderatetohigh
risk
bia
suggest
properli
design
clinic
trial
convalesc
plasma
use
sever
respiratori
infect
need
potent
monoclon
antibodi
neutral
merscov
spike
protein
vitro
develop
howev
except
vivo
data
relat
use
convalesc
plasma
monoclon
antibodi
treatment
mer
current
lack
serum
hightitr
dromedari
camel
decreas
merscov
load
lung
mice
transduc
human
ref
human
polyclon
antibodi
spike
protein
gener
vaccin
transchromosom
bovin
treatment
antibodi
reduc
viral
titr
lung
mice
treatment
administ
hour
challeng
merscov
mice
also
treat
human
neutral
monoclon
antibodi
direct
receptorbind
domain
merscov
spike
protein
day
merscov
challeng
treatment
also
decreas
viral
titr
lung
neutral
antibodi
obtain
convalesc
patient
produc
recombinantli
human
neutral
monoclon
antibodi
also
provid
benefit
mice
express
human
challeng
merscov
human
neutral
monoclon
antibodi
reduc
merscov
replic
lung
rabbit
follow
prophylact
therapeut
treatment
treatment
rhesu
macaqu
human
monoclon
antibodi
day
challeng
result
reduc
lung
patholog
studi
viral
replic
complet
inhibit
patholog
alter
lung
despit
therapi
furthermor
none
studi
address
potenti
emerg
escap
mutant
vivo
altern
antibodi
target
region
bind
spike
protein
could
use
prevent
entri
merscov
approach
success
vitro
howev
whether
treatment
would
feasibl
would
substanti
advers
effect
human
remain
determin
hostdirect
strategi
also
limit
viral
replic
exampl
spike
protein
sarscov
cleav
cathepsin
b
cathepsin
l
transmembran
proteas
serin
possibl
host
proteas
inhibit
host
serin
proteas
camostat
reduc
entri
sarscov
increas
surviv
mous
model
howev
target
host
proteas
like
result
undesir
side
effect
target
viral
proteas
anoth
underappreci
strategi
attenu
detriment
host
respons
develop
treatment
would
requir
thorough
understand
host
respons
involv
acut
lung
injuri
ard
process
unfortun
poorli
understood
moment
nonetheless
vitro
studi
limit
studi
anim
model
respiratori
virus
shown
anaphylatoxin
import
develop
acut
lung
injuri
block
anaphylatoxin
reduc
lung
patholog
vaccin
contain
immunogen
part
pathogen
rather
entir
pathogen
vaccin
base
direct
introduct
plasmid
encod
antigen
follow
situ
product
antigen
immun
respons
mount
chang
gene
express
vitro
merscov
infect
use
predict
potenti
effect
drug
one
drug
predict
efficaci
kinas
inhibitor
modestli
inhibit
sarscov
merscov
replic
follow
treatment
cell
prior
infect
treatment
infect
inhibit
replic
sarscov
merscov
vaccin
vaccin
could
use
prevent
infect
reduc
diseas
sever
viral
shed
therebi
transmiss
thu
help
control
mer
outbreak
sever
vaccin
strategi
develop
sarscov
test
anim
inactiv
viru
liveattenu
viru
viral
vector
subunit
vaccin
recombin
protein
dna
vaccin
similar
approach
use
develop
experiment
merscov
vaccin
date
three
merscov
vaccin
evalu
nonhuman
primat
one
studi
rhesu
macaqu
prime
dna
encod
spike
protein
follow
boost
spike
dna
recombin
protein
consist
spike
subunit
contain
receptorbind
domain
prime
boost
subunit
protein
approach
reduc
patholog
chang
lung
function
anim
infect
merscov
week
last
vaccin
moreov
three
vaccin
recombinantli
express
protein
contain
receptorbind
domain
spike
protein
reduc
viral
load
lung
patholog
rhesu
macaqu
infect
week
last
vaccin
three
dna
vaccin
construct
encod
fulllength
spike
sequenc
reduc
viral
load
patholog
lung
challeng
merscov
week
last
vaccin
one
concern
vaccin
human
vaccinemedi
enhanc
diseas
process
diseas
follow
infect
sever
vaccin
individu
unvaccin
individu
although
observ
small
subset
vaccin
studi
carri
sarscov
yet
observ
publish
merscov
vaccin
studi
import
concern
moreov
unclear
vaccin
merscov
healthi
individu
seem
littl
risk
sever
diseas
older
patient
patient
underli
diseas
highest
risk
sever
mer
would
import
target
popul
howev
vaccin
patient
problemat
owe
poor
immun
respons
establish
influenza
viru
addit
vaccin
peopl
high
risk
exposur
merscov
health
care
worker
slaughterhous
worker
camel
herder
advis
understand
pathogenesi
emerg
coronavirus
increas
opportun
ration
design
therapeut
target
viral
replic
immunopatholog
ration
design
new
drug
repurpos
exist
compound
alreadi
result
develop
plpro
inhibitor
identif
kinas
inhibitor
inhibit
replic
sarscov
merscov
vitro
howev
potenti
treatment
progress
past
identif
effect
vitro
vivo
studi
select
promis
treatment
option
requir
develop
sever
mous
model
mer
thu
import
step
forward
box
owe
acut
natur
mer
import
role
immunopatholog
combin
therapi
aim
simultan
inhibit
viral
replic
limit
viral
dissemin
dampen
host
respons
like
yield
best
result
furthermor
treatment
start
earli
possibl
rather
wait
patient
alreadi
develop
extens
lung
damag
develop
therapi
sar
mer
need
focu
test
human
properli
control
clinic
trial
current
nonstandard
uncontrol
approach
treatment
inform
may
benefici
patient
recent
ebola
outbreak
demonstr
rapid
clinic
trial
design
approv
possibl
except
situat
call
deviat
normal
procedur
treatment
develop
evalu
prevent
viral
transmiss
key
reduc
burden
mer
larg
proport
nosocomi
merscov
infect
indic
prevent
measur
hospit
current
either
fulli
implement
insuffici
prevent
zoonot
transmiss
dromedari
camel
anoth
possibl
decreas
number
mer
case
understand
pathogenesi
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
come
anim
studi
ideal
model
recapitul
specif
aspect
human
diseas
sever
mous
model
establish
exampl
use
mouseadapt
sar
coronaviru
sarscov
express
human
receptor
mice
although
recogn
mice
might
poorli
mimic
specif
human
respons
infect
avail
knockout
transgen
mice
enabl
target
studi
virushost
interact
sever
nonhuman
primat
model
develop
sarscov
mer
coronaviru
merscov
close
relationship
nonhuman
primat
human
often
allow
faith
recapitul
diseas
host
respons
howev
benefit
counter
need
special
husbandri
sometim
limit
avail
anim
reagent
high
cost
pathogenesi
sarscov
merscov
respect
reservoir
host
nearli
well
studi
human
current
one
experimentalinfect
studi
carri
bat
merscov
none
carri
coronavirus
thu
data
mostli
limit
detect
coronavirus
natur
infect
bat
detect
coronavirus
mainli
faecal
sampl
bat
oral
swab
suggest
replic
bat
occur
predominantli
gastrointestin
tract
contrast
combin
intratrach
intranas
inocul
mask
palm
civet
sarscov
result
interstiti
pneumonia
oral
rectal
viral
shed
pathogenesi
merscov
dromedari
camel
studi
experiment
limit
number
anim
anim
develop
transient
mild
diseas
howev
larg
quantiti
merscov
shed
upper
respiratori
tract
line
predomin
replic
merscov
nasal
turbin
larynx
anim
explain
frequent
zoonot
transmiss
first
vaccin
merscov
test
dromedari
camel
inde
camel
vaccin
modifi
vaccinia
viru
express
merscov
spike
protein
subsequ
challeng
anim
merscov
result
less
viral
shed
unvaccin
anim
therebi
potenti
limit
transmiss
naiv
anim
human
certainli
progress
develop
vaccin
therapi
emerg
coronavirus
research
rigor
test
requir
success
combat
novel
pathogen
sever
acut
respiratori
syndrom
sar
outbreak
develop
first
pandem
twentyfirst
centuri
becam
clear
medic
scientif
commun
adequ
prepar
emerg
highli
pathogen
virus
wherea
sever
month
elaps
sever
thousand
case
sar
observ
caus
agent
identifi
sar
coronaviru
sarscov
subsequ
advanc
molecular
diagnost
tool
next
gener
sequenc
meant
middl
east
respiratori
syndrom
coronaviru
merscov
identifi
caus
larg
outbreak
mer
avail
fulllength
genom
merscov
enabl
rapid
develop
distribut
diagnost
assay
first
anim
model
diseas
sever
treatment
efficaci
studi
identif
reservoir
follow
soon
unfortun
sar
pandem
yield
solid
clinic
data
efficaci
treatment
regimen
data
urgent
need
treatment
mer
well
prepar
novel
coronavirus
may
emerg
sever
studi
use
synthet
biolog
studi
zoonot
transmiss
potenti
sarscovlik
virus
bat
ebola
viru
outbreak
west
africa
highlight
need
fasttrack
potenti
treatment
sever
clinic
trial
start
toward
end
outbreak
combin
experi
outbreak
sar
mer
ebola
provid
blueprint
respons
emerg
pathogen
identif
caus
agent
diagnost
assay
need
develop
distribut
rapidli
simultan
awar
new
syndrom
report
suspect
case
must
increas
addit
infect
control
measur
health
care
facil
essenti
research
need
focu
understand
epidemiolog
includ
pathogen
transmiss
identif
reservoir
andor
intermedi
host
anim
model
need
develop
well
therapeut
prophylact
measur
final
promis
treatment
need
fasttrack
clinic
trial
